Silence Therapeutics plc, (LON:SLN) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that the US Patent and Trade Mark Office yesterday granted US patent application 15/589,968 as US Patent 9,790,501 and US patent application 15/594,438 as US Patent 9,790,505.
Silence previously reported issuance of a notice of allowance for US patent application 15/589,968 on 15 August 2017 and for US patent application 15/594,438 on 11 September 2017.
The allowed claims of US Patents 9,790,501 and 9,790,505 will provide Silence with further protection for its innovative chemical modification technology in the US. Silence believes that these newly granted claims are relevant to third-party RNAi medicines, including Alnylam Pharmaceuticals’ products such as Patisiran, Fitusiran, Inclisiran, Givosiran and Cemdisiran.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics plc, commented: “These grants provide further protection for our US patent estate. We now have ten granted US patents, one US patent application, three granted European patents and four European patent applications encompassing our chemical modification technology. Our chemical modification patent portfolio also encompasses patents and patent applications in the following countries: Australia, Brazil, Canada, China, Israel, India, Japan, Korea, Mexico and South Africa.
“We continue to believe that several third party late-stage RNAi candidates require licences under our chemical modification patent portfolio. This includes Alnylam Pharmaceuticals’ products such as Patisiran, Fitusiran, Inclisiran, Givosiran and Cemdisiran.”